Anna Norhammar

List of Publications by Citations

93 papers	6,896 citations	35 h-index	83 g-index
107 ext. papers	8,733 ext. citations	7.6 avg, IF	5.5 L-index

#	Paper	IF	Citations
93	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal*, **2020**, 41, 255-323	9.5	1360
92	Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. *Circulation*, **1999**, 99, 2626-32	16.7	1052
91	Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. *Lancet, The*, **2002**, 359, 2140-4	40	791
90	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). *Circulation*, **2017**, 136, 249-259	16.7	519
89	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. *Journal of the American College of Cardiology*, **2018**, 71, 2628-2639	15.1	263
88	Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. *Journal of the American College of Cardiology*, **2004**, 43, 585-91	15.1	216
87	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 709-717	18.1	208
86	Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. *European Heart Journal*, **2004**, 25, 1990-7	9.5	169
85	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 344-351	6.7	124
84	Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study. *Circulation*, **2016**, 133, 576-83	16.7	120
83	The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. *European Heart Journal*, **2008**, 29, 166-76	9.5	120
82	Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. *Heart*, **2007**, 93, 1577-83	5.1	111
81	Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. *Diabetes Care*, **2003**, 26, 2770-6	14.6	92
80	Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. *European Heart Journal*, **2003**, 24, 838-44	9.5	85
79	Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. *Diabetologia*, **2011**, 54, 1308-17	10.3	82
78	Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. *Diabetologia*, **2016**, 59, 1692-701	10.3	70
77	Type 2 diabetes and cardiovascular disease in women. *Diabetologia*, **2013**, 56, 1-9	10.3	69

76	Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. *Diabetes Care*, **2008**, 31, 36-8	14.6	69
75	SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. *Journal of the American College of Cardiology*, **2018**, 71, 2497-2506	15.1	68
74	Abnormal glucose tolerance--a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. *Journal of Internal Medicine*, **2004**, 256, 288-97	10.8	63
73	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 831-841	6.7	60
72	Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1983-1987	6.7	55
71	Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 627-33	18.1	54
70	Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. *Journal of the American College of Cardiology*, **2016**, 68, 1404-1416	15.1	53
69	Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. *Diabetes Research and Clinical Practice*, **2016**, 117, 39-47	7.4	49
68	Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. *Diabetologia*, **2005**, 48, 2229-35	10.3	48
67	How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. *Diabetes, Obesity and Metabolism*, **2019**, 21, 968-974	6.7	46
66	Hyperglycaemia and cardiovascular disease. *Journal of Internal Medicine*, **2007**, 262, 145-56	10.8	42
65	IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. *Diabetes Care*, **2007**, 30, 2343-8	14.6	42
64	Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1136-1145	6.7	42
63	High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. *Circulation: Cardiovascular Interventions*, **2015**, 8, e002328	6	41
62	Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. *Diabetes and Vascular Disease Research*, **2006**, 3, 52-6	3.3	39
61	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1607-1618	6.7	38
60	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 606-615	18.1	37
59	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. *Diabetes Research and Clinical Practice*, **2017**, 123, 199-208	7.4	35

58	Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. *Diabetes and Vascular Disease Research*, **2015**, 12, 23-32	3.3	34
57	Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. *European Journal of Heart Failure*, **2014**, 16, 409-18	12.3	33
56	Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to Coronary Artery Disease). *PLoS ONE*, **2015**, 10, e0126370	3.7	32
55	Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. *European Journal of Preventive Cardiology*, **2017**, 24, 52-60	3.9	30
54	Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. *Heart*, **2015**, 101, 1139-48	5.1	28
53	Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. *EuroIntervention*, **2010**, 5, 891-897	3.1	24
52	Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. *Diabetologia*, **2006**, 49, 2247-55	10.3	22
51	Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. *Diabetologia*, **2012**, 55, 2109-17	10.3	21
50	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. *Diabetes and Vascular Disease Research*, **2018**, 15, 494-503	3.3	21
49	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. *Endocrinology, Diabetes and Metabolism*, **2018**, 1, e00036	2.7	18
48	Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. *Diabetes and Vascular Disease Research*, **2017**, 14, 77-87	3.3	16
47	Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 75-85	6.7	16
46	High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: A nationwide report. *Diabetes and Vascular Disease Research*, **2018**, 15, 31-38	3.3	15
45	Implications of abnormal glucose metabolism in patients with coronary artery disease. *Diabetes and Vascular Disease Research*, **2008**, 5, 285-90	3.3	15
44	Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. *Diabetes and Vascular Disease Research*, **2009**, 6, 71-9	3.3	14
43	Periodontal disease - important to consider in cardiovascular disease prevention. *Expert Review of Cardiovascular Therapy*, **2016**, 14, 987-9	2.5	14
42	Severe Periodontitis Is Associated with Myocardial Infarction in Females. *Journal of Dental Research* , **2018**, 97, 1114-1121	8.1	13
41	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). *European Journal of Heart Failure*, **2021**, 23, 1499-1511	12.3	13

40	Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014. *PharmacoEconomics - Open*, **2018**, 2, 393-402	2.1	11
39	Diabetes and cardiovascular mortality: the impact of sex. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 517-519	18.1	10
38	The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. *Diabetes and Vascular Disease Research*, **2014**, 11, 290-293	3.3	10
37	Symptoms of depression and their relation to myocardial infarction and periodontitis. *European Journal of Cardiovascular Nursing*, **2017**, 16, 468-474	3.3	8
36	Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. *Diabetes and Vascular Disease Research*, **2017**, 14, 69-76	3.3	8
35	Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. *Diabetes Care*, **2019**, 42, 1504-1511	14.6	8
34	Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2651-2659	6.7	8
33	Antiphospholipid Antibodies in Patients With Myocardial Infarction. *Annals of Internal Medicine*, **2019**, 170, 277-280	8	8
32	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. *Diabetes Care*, **2018**, 41, e106-e108	14.6	8
31	Mortality and extent of coronary artery disease in 2776 patients with type 1 diabetes undergoing coronary angiography: A nationwide study. *European Journal of Preventive Cardiology*, **2017**, 24, 848-857	3.9	7
30	Characteristics and Prognosis in Women and Men With Type 1 Diabetes Undergoing Coronary Angiography: A Nationwide Registry Report. *Diabetes Care*, **2018**, 41, 876-883	14.6	7
29	Invasive Dental Treatment and Risk for a First Myocardial Infarction. *Journal of Dental Research*, **2018**, 97, 1100-1105	8.1	7
28	Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2021**, 7, 104-111	6.4	7
27	Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management. *Diabetes Care*, **2020**, 43, 2001-2009	14.6	7
26	Saliva and plasma levels of cardiac-related biomarkers in post-myocardial infarction patients. *Journal of Clinical Periodontology*, **2017**, 44, 692-699	7.7	6
25	Elevated admission glucose is common and associated with high short-term complication burden after acute myocardial infarction: Insights from the VALIDATE-SWEDEHEART study. *Diabetes and Vascular Disease Research*, **2019**, 16, 582-584	3.3	6
24	Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". *Circulation*, **2018**, 137, 989-991	16.7	6
23	Prognosis in Patients With Diabetes Mellitus and STEMI Undergoing Primary PCI. *Journal of the American College of Cardiology*, **2018**, 72, 1427-1428	15.1	6

22	Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. *Diabetes and Vascular Disease Research*, **2016**, 13, 307-11	3.3	5
21	Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. *Diabetes Care*, **2021**, 44, 1211-1218	14.6	5
20	Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. *European Journal of Preventive Cardiology*, **2020**, 27, 1890-1901	3.9	4
19	Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1431-1435	6.7	4
18	Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort. *Diabetes and Vascular Disease Research*, **2018**, 15, 387-395	3.3	3
17	Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity. *Growth Hormone and IGF Research*, **2015**, 25, 298-303	2	3
16	Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry. *Diabetes and Vascular Disease Research*, **2020**, 17, 1479164120973676	3.3	3
15	Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study. *International Journal of Cardiology*, **2021**, 330, 23-29	3.2	3
14	The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry). *European Heart Journal Quality of Care & Clinical Outcomes*, **2021**, 7, 431-437	4.6	3
13	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. *Cardiovascular Diabetology*, **2021**, 20, 159	8.7	3
12	Hospitalization for Heart Failure and Death in New Users of SGLT-2 Inhibitors in Patients With and Without Cardiovascular Disease□CVD Real Study. *Canadian Journal of Diabetes*, **2017**, 41, S51-S52	2.1	2
11	Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort. *Diabetes and Vascular Disease Research*, **2019**, 16, 22-27	3.3	2
10	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. *Diabetes Care*, **2018**, 41, e104-e105	14.6	2
9	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. *Diabetes and Vascular Disease Research*, **2020**, 17, 1479164120922123	3.3	1
8	Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c. *Cardiovascular Diabetology*, **2021**, 20, 122	8.7	1
7	Endodontic inflammatory disease: A risk indicator for a first myocardial infarction. *International Endodontic Journal*, **2022**, 55, 6-17	5.4	1
6	Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure. *Cardiovascular Diabetology*, **2021**, 20, 227	8.7	0
5	Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes. *Journal of the American Heart Association*, **2021**, 10, e022667	6	0

4	Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. *Cardiovascular Diabetology*, **2021**, 20, 38	8.7	0
3	Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries. *Diabetes Research and Clinical Practice*, **2021**, 177, 108822	7.4	0
2	Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it?: reply. *European Heart Journal*, **2008**, 29, 2058-2059	9.5	
1	Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504-1511. *Diabetes Care*, **2020**, 43, e9	14.6	